甲状腺癌放射性碘消融治疗的争议：谁能从中获益？

Controversy over radioiodine ablation in thyroid cancer: who benefits?

作者信息

Yoo Don C, Noto Richard B, Mazzaglia Peter J

机构信息

Department of Diagnostic Imaging, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA.

出版信息

Surg Clin North Am. 2014 Jun;94(3):573-86. doi: 10.1016/j.suc.2014.03.004.

DOI:10.1016/j.suc.2014.03.004

PMID:24857577

Abstract

Recent studies have proposed that overdiagnosis is probably the principal cause of the increased incidence of thyroid cancer. The controversy around radioiodine ablation is complicated by the ever increasing numbers of small, low-risk thyroid cancers being diagnosed. This article examines the history and evolving epidemiology of the disease and treatment.

摘要

最近的研究表明，过度诊断可能是甲状腺癌发病率上升的主要原因。随着诊断出的小的、低风险甲状腺癌数量不断增加，围绕放射性碘消融的争议变得更加复杂。本文探讨了该疾病及其治疗方法的历史和不断演变的流行病学。